Vertex Pharmaceuticals has completed submission of its rolling BLA for povetacicept seeking accelerated approval for IgAN treatment in adults, using a priority review voucher for expedited six-month FDA review.
Key takeaways
Completed rolling BLA submission to FDA for povetacicept for IgAN in adults.
Seeking potential accelerated approval.
Used priority review voucher to expedite FDA review to six months from acceptance versus typical ten months.
Forward-looking statements subject to risks including potential delays in regulatory approval.